- UK Government has extended its contract with Wockhardt.
- Extension of contract creates 40 new jobs.
- Under the extanded contract, a Wrexham factory is aiding the production of COVID-19 vaccines.
- The UK Government wants to ensure huge supply and long availability of COVID vaccine.
- UK is going through lockdown.
The United Kingdom (UK) government has extended its 18-month contract with Wockhardt for six more months. CP Pharmaceuticals, a subsidiary of Wockhardt is working on to develop COVID vaccine. Now production can continue at CP Pharmaceuticals until AUG 2022. UK is struggling to combat COVID-19 with complete lockdown being imposed once again.
The UK International Trade Secretary Liz Truss said that extension of contract was a brilliant bit of news for people in Wrexham. She added that the extension of contract would bring important investment to the local area, creating more jobs and provide security to the community as UK battled the coronavirus which originated in Wuhan, China.
Business Secretary Kwasi Kwarteng said that by extending contract with Wockhardt, UK Government would ensure that the UK had uninterrupted fill and finish capacity of COVID vaccine whose huge supply would protect the British public in the long-term.
Having a presence in Wrexham for over 20 years, pharmaceutical company has created jobs for 400 people at its manufacturing facility that is located at Wrexham Industrial Estate. Founder Chairman, Dr Habil Khorakiwala said that the arrangement brought in a huge sense of purpose and pride, upholding ongoing global commitment of his company to fight against an unprecedented pandemic.